🚀 VC round data is live in beta, check it out!
Jilin Aodong Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jilin Aodong and similar public comparables like Beam Therapeutics, Gland Pharma, Alumis, Catalyst Pharmaceuticals and more.
Jilin Aodong Overview
About Jilin Aodong
Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others.
Founded
2000
HQ
Employees
29
Website
Sectors
Financials (FY)
EV
$3B
Jilin Aodong Financials
Jilin Aodong reported last fiscal year revenue of $342M and EBITDA of $394M.
In the same fiscal year, Jilin Aodong generated $165M in gross profit, $394M in EBITDA, and $351M in net income.
Jilin Aodong P&L
In the most recent fiscal year, Jilin Aodong reported revenue of $342M and EBITDA of $394M.
Jilin Aodong expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $342M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $165M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | — | XXX | $394M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 115% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (3%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $351M | XXX | XXX | XXX |
| Net Margin | — | XXX | 103% | XXX | XXX | XXX |
| Net Debt | — | — | $152M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jilin Aodong Stock Performance
Jilin Aodong has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Jilin Aodong's stock price is $2.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.0% | XXX | XXX | XXX | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJilin Aodong Valuation Multiples
Jilin Aodong trades at 9.0x EV/Revenue multiple, and 7.8x EV/EBITDA.
Jilin Aodong Financial Valuation Multiples
As of April 18, 2026, Jilin Aodong has market cap of $3B and EV of $3B.
Equity research analysts estimate Jilin Aodong's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jilin Aodong has a P/E ratio of 9.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (332.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 18.6x | XXX | XXX | XXX |
| P/E | — | XXX | 9.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 145.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jilin Aodong Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jilin Aodong Margins & Growth Rates
Jilin Aodong's revenue in the last fiscal year declined by (11%).
Jilin Aodong's revenue per employee in the last FY averaged $11.8M, while opex per employee averaged $6.0M for the same period.
Jilin Aodong Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 115% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $11.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $6.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jilin Aodong Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jilin Aodong | XXX | XXX | XXX | XXX | XXX | XXX |
| Beam Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Gland Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alumis | XXX | XXX | XXX | XXX | XXX | XXX |
| Catalyst Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Almirall | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jilin Aodong M&A Activity
Jilin Aodong acquired XXX companies to date.
Last acquisition by Jilin Aodong was on XXXXXXXX, XXXXX. Jilin Aodong acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jilin Aodong
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJilin Aodong Investment Activity
Jilin Aodong invested in XXX companies to date.
Jilin Aodong made its latest investment on XXXXXXXX, XXXXX. Jilin Aodong invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jilin Aodong
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jilin Aodong
| When was Jilin Aodong founded? | Jilin Aodong was founded in 2000. |
| Where is Jilin Aodong headquartered? | Jilin Aodong is headquartered in China. |
| How many employees does Jilin Aodong have? | As of today, Jilin Aodong has over 29 employees. |
| Is Jilin Aodong publicly listed? | Yes, Jilin Aodong is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Jilin Aodong? | Jilin Aodong trades under 000623 ticker. |
| When did Jilin Aodong go public? | Jilin Aodong went public in 1996. |
| Who are competitors of Jilin Aodong? | Jilin Aodong main competitors are Beam Therapeutics, Gland Pharma, Alumis, Catalyst Pharmaceuticals. |
| What is the current market cap of Jilin Aodong? | Jilin Aodong's current market cap is $3B. |
| What is the current revenue of Jilin Aodong? | Jilin Aodong's last fiscal year revenue is $342M. |
| What is the current EV/Revenue multiple of Jilin Aodong? | Current revenue multiple of Jilin Aodong is 9.0x. |
| Is Jilin Aodong profitable? | No, Jilin Aodong is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.